Here are six observations:
1. The market is expected to hit $49.41 billion by 2021.
2. More regenerative medicine research in orthopedic spine and dermatology is driving market growth.
3. Pharmaceutical and biotechnology company investments in regenerative medicines, such as cells therapies and immunotherapy, is also spurring market growth.
4. North America dominates the global market, due to the rising number of organ transplantations and increasing research into the use of regenerative medicine in orthopedic musculoskeletal spine, oncology and cardiovascular diseases.
5. A lack of experienced professionals in the field and required hefty investments serve as obstacles to market growth.
6. Celgene, Acelity, StemCells and Organogenesis lead the space.
More articles on devices:
Zimmer Biomet to present clinical data on Aspen MIS Fusion System & Timberline Systems at CNS meeting: 5 highlights
AxioMed receives Australian market approval for Freedom Viscoelastic Disc Replacement technology: 5 points
The Center for Musculoskeletal Disorders is 1st in Northeast to install Renaissance system in ambulatory outpatient setting: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
